HUTCHMED (China) Limited (NASDAQ:HCM) Short Interest Update

HUTCHMED (China) Limited (NASDAQ:HCM) was the target of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 474,900 shares, a decrease of 7.2% from the July 15th total of 511,600 shares. Based on an average daily volume of 145,600 shares, the short-interest ratio is currently 3.3 days.

HUTCHMED Stock Down 2.7 %

HUTCHMED stock opened at $17.97 on Wednesday. The company has a quick ratio of 2.60, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. HUTCHMED has a 52 week low of $11.93 and a 52 week high of $21.92. The business’s 50-day moving average price is $18.41 and its 200 day moving average price is $17.63.

Wall Street Analyst Weigh In

Several analysts recently commented on HCM shares. StockNews.com lowered HUTCHMED from a “buy” rating to a “hold” rating in a report on Thursday, July 18th. The Goldman Sachs Group raised their target price on HUTCHMED from $17.00 to $19.00 and gave the stock a “neutral” rating in a report on Thursday, August 1st.

Institutional Trading of HUTCHMED

Several institutional investors have recently bought and sold shares of HCM. M&G Plc acquired a new stake in HUTCHMED in the first quarter valued at approximately $4,458,000. Hsbc Holdings PLC grew its holdings in HUTCHMED by 821.2% in the fourth quarter. Hsbc Holdings PLC now owns 206,544 shares of the company’s stock valued at $3,720,000 after purchasing an additional 184,123 shares during the period. Renaissance Technologies LLC grew its holdings in HUTCHMED by 74.8% in the second quarter. Renaissance Technologies LLC now owns 131,300 shares of the company’s stock valued at $2,248,000 after purchasing an additional 56,200 shares during the period. Bellevue Group AG grew its holdings in HUTCHMED by 2.1% in the first quarter. Bellevue Group AG now owns 1,154,632 shares of the company’s stock valued at $19,398,000 after purchasing an additional 23,521 shares during the period. Finally, Point72 Asset Management L.P. acquired a new stake in HUTCHMED in the second quarter valued at approximately $279,000. 8.82% of the stock is owned by institutional investors and hedge funds.

HUTCHMED Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.